Research Article
The Effect of Bevacizumab and Propranolol on Nasal Polyposis
Table 1
Expression of VEGF-A, Ang-1, Ang-2 in each group. (−: negative expression, +: Low expression, ++: Moderate expression and +++: High expression).
| | VEGF-A | Ang-1 | Ang-2 |
| Group 1: Healthy nasal mucosa (control group) | − | + | +++ | Group 2: Nasal polyposis group without any treatment | + | ++ | + | Group 3: Nasal polyposis + propranolol | − | − | ++ | Group 4 (n : 7): Nasal polyposis + bevacizumab | − | − | ++ |
|
|